---
title: "Veracyte: Strong Earnings Beat, Raised Guidance and Emerging Diagnostics Portfolio Support Durable Upside, Justifying Buy Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294488048.md"
description: "William Blair analyst Matt Larew maintained a Buy rating on Veracyte (VCYT) on July 15, citing strong earnings beats, raised full-year guidance, and promising traction from emerging diagnostics like Prosigna and TrueMRD. Piper Sandler also initiated coverage with a Buy rating and a $66 price target. The analysts highlight the company's valuation discount and durable upside potential supported by established franchises and new product growth."
datetime: "2026-07-31T08:45:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294488048.md)
  - [en](https://longbridge.com/en/news/294488048.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294488048.md)
---

# Veracyte: Strong Earnings Beat, Raised Guidance and Emerging Diagnostics Portfolio Support Durable Upside, Justifying Buy Rating

William Blair analyst Matt Larew has maintained their bullish stance on VCYT stock, giving a Buy rating on July 15.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Matt Larew has given his Buy rating due to a combination of factors tied to Veracyte’s strong financial and operational performance. The company exceeded expectations on both revenue and adjusted EBITDA, prompting management to lift full-year guidance and refine growth targets for its core Afirma and Decipher franchises, which continue to show solid volume expansion despite some moderation in lower-risk Decipher usage.

He also highlights the strategic importance of newly launched Prosigna and TrueMRD, which are gaining early traction and have recently achieved key milestones such as reimbursement and positive clinical trial results, positioning them as meaningful future growth drivers. Taken together with the stock’s valuation discount versus relevant diagnostics peers, Larew views Veracyte’s combination of established growth platforms and emerging products as supporting durable, long-term upside potential, justifying his Buy recommendation.

According to TipRanks, Larew is a 4-star analyst with an average return of 10.3% and a 57.25% success rate. Larew covers the Healthcare sector, focusing on stocks such as Repligen, Option Care Health, and Thermo Fisher.

In another report released on July 15, Piper Sandler also initiated coverage with a Buy rating on the stock with a $66.00 price target.

### Related Stocks

- [VCYT.US](https://longbridge.com/en/quote/VCYT.US.md)
- [RGEN.US](https://longbridge.com/en/quote/RGEN.US.md)
- [OPCH.US](https://longbridge.com/en/quote/OPCH.US.md)
- [TMO.US](https://longbridge.com/en/quote/TMO.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)

## Related News & Research

- [Veracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests](https://longbridge.com/en/news/294746901.md)
- [Guggenheim Reaffirms Their Buy Rating on Veracyte (VCYT)](https://longbridge.com/en/news/294705162.md)
- [Scotiabank Sticks to Its Buy Rating for Nexxen International (NEXN)](https://longbridge.com/en/news/295815126.md)
- [Will Nu Holdings (NU) Stock Rise or Fall After Q2 2026 Earnings?](https://longbridge.com/en/news/295814798.md)
- [VCYT: Double-digit revenue growth, new product launches, and raised 2026 guidance highlight strong Q2](https://longbridge.com/en/news/294409646.md)